Transpire Bio Achieves FDA Filing Acceptance for Generic High-Strength Trelegy Ellipta with Potential 180-Day Market Exclusivity
核心洞察
Transpire Bio's ANDA for generic high-strength Trelegy Ellipta (200 mcg/62.5 mcg/25 mcg) has been accepted for filing by the U.S. FDA.
The company believes it was the first to file with Paragraph IV certification, potentially qualifying for 180 days of market exclusivity upon approval.
Trelegy Ellipta reported U.S. annual sales of $8 billion in 2025, representing a significant market opportunity for affordable generic alternatives.
Transpire Bio Inc. (搜索) announced that the U.S. Food and Drug Administration (搜索) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of high-strength Trelegy Ellipta (200 mcg/62.5 mcg/25 mcg). The clinical-stage biopharmaceutical company, which develops inhaled therapeutics for pulmonary and systemic diseases, filed the ANDA for fluticasone furoate, umeclidinium, and vilanterol inhalation powder.
First-to-File Status and Market Exclusivity Potential
Based on FDA public records, Transpire Bio believes it was the first company to file an ANDA for the high-strength product with a Paragraph IV certification under the Hatch-Waxman Act provisions. If the FDA approves Transpire Bio's ANDA, the company believes it will be eligible for 180 days of market exclusivity.
The original Trelegy Ellipta is indicated in the U.S. for maintenance treatment of asthma (搜索) in patients 18 years and older and for maintenance treatment of patients with chronic obstructive pulmonary disease (搜索) (COPD (搜索)). According to IQVIA data, Trelegy Ellipta reported U.S. annual sales of $8 billion in 2025.
Strategic Milestone for Complex Generic Portfolio
"The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy Ellipta is another major milestone in advancing our development program and our complex generic franchise as a whole," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "Our highly experienced team in South Florida continues to meet and exceed each challenge put in front of them. With our first two ANDAs for generic Breo (搜索) and Trelegy now confirmed as first-to-file, and this ANDA as our potentially third first-to-file, we move one step closer to providing patients suffering from asthma (搜索) or COPD (搜索) with an affordable option and improved access to this critical medication."
Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio, emphasized the technical achievement: "This milestone demonstrates Transpire Bio's strong capabilities in developing complex drug device combination products. We are extremely proud of the deep scientific and technical competence of our Transpire Bio team to constantly execute against our strategic plan."
Broader Pipeline Development
Beyond its complex generic franchise, Transpire Bio is developing a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (搜索) (IPF (搜索)) and Progressive Pulmonary Fibrosis (搜索) (PPF (搜索)), with three assets currently in development. The company is also advancing therapies for Pulmonary Arterial Hypertension (搜索) (PAH (搜索)), Diabetes (搜索), Obesity (搜索), Parkinson's Disease Psychosis (搜索), and Glioblastoma (搜索). All products are being developed and manufactured in Transpire Bio's state-of-the-art manufacturing facilities located in South Florida.